<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00176917</url>
  </required_header>
  <id_info>
    <org_study_id>UMN-MT1999-07</org_study_id>
    <secondary_id>0104M93821</secondary_id>
    <nct_id>NCT00176917</nct_id>
    <nct_alias>NCT00005899</nct_alias>
  </id_info>
  <brief_title>Stem Cell Transplantation for Hurler</brief_title>
  <official_title>Hematopoietic Stem Cell Transplantation for Hurler Syndrome, Maroteaux Lamy Syndrome (MPS VI), and Alpha Mannosidase Deficiency (Mannosidosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and engraftment of donor hematopoietic
      cells using this conditioning regimen in patients undergoing a hematopoietic (blood forming)
      cell transplant for Hurler syndrome, Maroteaux Lamy syndrome, Mannosidosis, or I-cell
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior to transplantation, subjects will receive Busulfan intravenously (IV) via the Hickman
      line four times daily for 4 days, Cyclophosphamide intravenously via the Hickman line once a
      day for 4 days, and Anti-Thymocyte Globulin IV via the Hickman line twice daily for three
      days before the transplant. These three drugs are being given to subjects to help the new
      marrow &quot;take&quot; and grow.

      On the day of transplantation, the donor's hematopoietic cells will be transfused via central
      venous catheter.

      After hematopoietic cell transplant, subjects will then receive two drugs, cyclosporin and
      either methylprednisolone or Mycophenolate Mofetil (MMF). Cyclosporin and methylprednisolone
      or MMF are given to help prevent the complication of graft-versus-host disease and to
      decrease the chance that the new donor cells will be rejected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1999</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percentage of Donor Cells in Study Population (Chimerism).</measure>
    <time_frame>at 21 days, 42 days, 60 days, 100 days, 6 months, and 1 year</time_frame>
    <description>Donor-derived engraftment determined by restriction fragment length polymorphism (RFLP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Surviving on Study</measure>
    <time_frame>at 100 days, 1 year, and 3 years post transplant</time_frame>
    <description>Number of patients surviving (alive) at specified timepoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Failed Engraftment.</measure>
    <time_frame>Day 42 Post Transplant</time_frame>
    <description>Toxicity (undesireable effect) of hematologic donor cell engraftment is determined by failure to engraft at Day 42.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Grade III-IV Acute Graft-versus-host Disease (aGVHD).</measure>
    <time_frame>Day 100 Post Transplant</time_frame>
    <description>Toxicity (undesireable effect) of this stem cell transplant preparative regimen due to acute graft-versus-host disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Mucopolysaccharidosis I</condition>
  <condition>Mucopolysaccharidosis VI</condition>
  <condition>Mannosidosis</condition>
  <condition>Mucolipidosis Type II (I-cell Disease)</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients treated with chemotherapy and transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains the enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e. blood taken from the umbilical cord after a baby is born and umbilical cord is cut).</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Bone Marrow Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan, Cyclophosphamide, ATG</intervention_name>
    <description>Prior to transplantation, subjects will receive BUSULFAN intravenously (IV) via the Hickman line twice daily for 4 days, CYCLOPHOSPHAMIDE intravenously via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow &quot;take&quot; and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Busulfex, Cytoxan, Thymoglobulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Mucopolysaccharidosis, type I (e.g., Hurler syndrome), Maroteaux-Lamy
             syndrome (MPS VI), Alpha Mannosidosis, or mucolipidosis type II (I-cell disease) who
             have an HLA-identical or mismatched (at 1 antigen) related marrow, PBSC, or cord blood
             donor.

          -  Patients with Mucopolysaccharidosis, type I, Maroteaux-Lamy syndrome (MPS VI), Alpha
             Mannosidosis, or mucolipidosis type II (I-cell disease) who have an HLA-identical or
             HLA-1 antigen mismatched unrelated marrow, PBSC, or HLA-0-2 antigen mismatched
             umbilical cord blood donor.

          -  Patients with MPS type I, Maroteaux Lamy Syndrome (MPS VI), or mucolipidosis type II
             (I-cell disease) will have a mental developmental index within two standard deviations
             of the normal mean, as best as can be determined using Bayley scales of infant
             development or other standardized testing, recognizing that these may be affected by
             speech and/or hearing impairment.

          -  Adequate organ function:

          -  Cardiac: ejection fraction &gt;40%; no decompensated congestive heart failure or
             uncontrolled arrhythmia

          -  Renal: serum creatinine &lt;2.0 mg/dl

          -  Hepatic: total bilirubin &lt;3x Upper limits of normal transaminases &lt; 5.0 x Upper limits
             of normal

          -  Signed consent.

        Exclusion Criteria:

          -  Presence of major organ dysfunction (see above)

          -  Pregnancy

          -  Evidence of HIV infection or known HIV positive serology

          -  Patients or parents are psychologically incapable of undergoing BMT with associated
             strict isolation or documented history of medical non-compliance

          -  Patients &gt;50 kg may be at risk for having cell doses below the goal of â‰¥ 10 x 106 CD
             34 cells/kg and therefore will not be eligible to receive unrelated PBSCs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Orchard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>July 28, 2009</results_first_submitted>
  <results_first_submitted_qc>July 28, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 4, 2009</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stem cell transplant</keyword>
  <keyword>storage disease</keyword>
  <keyword>errors of metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
    <mesh_term>Mannosidase Deficiency Diseases</mesh_term>
    <mesh_term>alpha-Mannosidosis</mesh_term>
    <mesh_term>Mucolipidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis VI</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Transplant Patients</title>
          <description>Patients that received hematopoietic stem cell transplant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Transplant Patients</title>
          <description>Patients that received hematopoietic stem cell transplant.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percentage of Donor Cells in Study Population (Chimerism).</title>
        <description>Donor-derived engraftment determined by restriction fragment length polymorphism (RFLP).</description>
        <time_frame>at 21 days, 42 days, 60 days, 100 days, 6 months, and 1 year</time_frame>
        <population>Day 21 (24 patients included), Day 42 (15 pts), Day 60 (29 pts), Day 100 (25 pts), 6 Months (18 pts), 1 Year (16 pts).</population>
        <group_list>
          <group group_id="O1">
            <title>Transplant Patients</title>
            <description>Patients that received hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Donor Cells in Study Population (Chimerism).</title>
          <description>Donor-derived engraftment determined by restriction fragment length polymorphism (RFLP).</description>
          <population>Day 21 (24 patients included), Day 42 (15 pts), Day 60 (29 pts), Day 100 (25 pts), 6 Months (18 pts), 1 Year (16 pts).</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>21 Days Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.8" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 Days Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Days Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 Days Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Surviving on Study</title>
        <description>Number of patients surviving (alive) at specified timepoints.</description>
        <time_frame>at 100 days, 1 year, and 3 years post transplant</time_frame>
        <population>Day 100 and 1 Year timepoints include all 41 patients. Year 3 includes 36 patients (5 pts not yet at followup timepoint.)</population>
        <group_list>
          <group group_id="O1">
            <title>Transplant Patients</title>
            <description>Patients that received hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Surviving on Study</title>
          <description>Number of patients surviving (alive) at specified timepoints.</description>
          <population>Day 100 and 1 Year timepoints include all 41 patients. Year 3 includes 36 patients (5 pts not yet at followup timepoint.)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 100 Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Years Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Failed Engraftment.</title>
        <description>Toxicity (undesireable effect) of hematologic donor cell engraftment is determined by failure to engraft at Day 42.</description>
        <time_frame>Day 42 Post Transplant</time_frame>
        <population>1 patient of 41 failed engraftment - per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Transplant Patients</title>
            <description>Patients that received hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Failed Engraftment.</title>
          <description>Toxicity (undesireable effect) of hematologic donor cell engraftment is determined by failure to engraft at Day 42.</description>
          <population>1 patient of 41 failed engraftment - per protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Grade III-IV Acute Graft-versus-host Disease (aGVHD).</title>
        <description>Toxicity (undesireable effect) of this stem cell transplant preparative regimen due to acute graft-versus-host disease.</description>
        <time_frame>Day 100 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transplant Patients</title>
            <description>Patients that received hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Grade III-IV Acute Graft-versus-host Disease (aGVHD).</title>
          <description>Toxicity (undesireable effect) of this stem cell transplant preparative regimen due to acute graft-versus-host disease.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Transplant Patients</title>
          <description>Patients that received hematopoietic stem cell transplant.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Based on variability in age, diagnosis and condition of these patients, the data on enzyme levels and neuropsych testing is extremely difficult to report.
See Secondary Outcome Measures #3 and #4; no other adverse events were collected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Paul J. Orchard, M.D.</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-626-2313</phone>
      <email>orcha001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

